1 Cardiovascular Pharmacology Foundations
Learn how major cardiovascular medicine groups support treatment goals, what risks and interactions to watch for, and why monitoring and clinician-guided changes matter.
Treatment goals and patient factors
Cardiovascular medicines are selected to meet a clinical goal—such as lowering blood pressure, relieving congestion or angina, controlling heart rate or rhythm, or preventing clots—while minimizing harm. The best choice depends on the diagnosis, vital signs, kidney function, electrolytes, other medicines, and treatment response.
A medicine may serve more than one purpose, and different medicines used for the same condition may have distinct roles. Treatment choices and changes should be guided by a qualified clinician or pharmacist.
and ARBs
reduce angiotensin II formation. They can cause a persistent dry cough and, rarely, angioedema. An blocks angiotensin II receptors and may be considered as an alternative when cough occurs.
Both and ARBs can raise potassium and affect kidney function. They are generally not combined, and renin–angiotensin system medicines can be harmful during pregnancy. Monitoring and medication changes should be clinician-directed.
and heart rate
reduce heart rate and cardiac workload. A markedly slow pulse, faintness, low blood pressure, or conduction problems may warrant assessment and clinical guidance.
Do not independently increase or abruptly stop a chronic beta-blocker, since sudden withdrawal can be harmful.
and electrolyte risks
increase sodium and water excretion and can lower potassium and magnesium. Weakness or muscle cramps in someone taking one are reasons to assess electrolytes; volume status and kidney function should also be checked as directed.
can lower potassium and sodium and may raise uric acid. such as spironolactone retain potassium and can instead cause , especially with kidney impairment or other potassium-raising medicines.
Because spironolactone and can both raise potassium, check with a prescriber or pharmacist before starting potassium supplements or using salt substitutes. Kidney function and serum potassium may need monitoring.
and rhythm monitoring
alter cardiac electrical activity and may cause proarrhythmia—a new or worsened rhythm problem, including potentially serious rhythm disturbances. Monitoring with electrocardiograms and other tests depends on the specific drug and the patient’s risks.
Amiodarone has important pulmonary, hepatic, thyroid, and cardiac toxicities and drug interactions. New cough or shortness of breath while taking it warrants prompt clinical assessment.
and toxicity
is cleared mainly by the kidneys, so worsening renal function can increase exposure and toxicity risk. Possible symptoms include gastrointestinal, neurologic, visual, and rhythm changes; nausea, confusion, and visual changes in a person whose kidney function has worsened need prompt professional assessment.
Potassium and other clinical factors also matter. Do not adjust the dose independently when toxicity is suspected.
and medication interactions
Nitroglycerin increases nitric-oxide–cGMP signaling. PDE-5 inhibitors such as sildenafil can intensify its blood-pressure-lowering effect, so using them together is contraindicated because severe hypotension, fainting, or ischemia may result.
A person with chest pain who has recently taken sildenafil should seek urgent professional guidance rather than improvising medication use.
Dihydropyridine such as amlodipine primarily relax vascular smooth muscle and may cause ankle swelling. Non-dihydropyridines such as verapamil and diltiazem can also slow AV-node conduction and heart rate, and may cause bradycardia or constipation.
Combining medicines that slow heart rate requires clinical review, particularly when conduction is already impaired.
Heart failure and congestion
increase fluid excretion and can relieve congestion, such as worsening ankle swelling and breathlessness from fluid retention. Their use requires attention to blood pressure, kidney function, and electrolytes.
Heart-failure medicines have different roles: some improve symptoms, while others are chosen to reduce disease progression or risk. The regimen depends on the type of heart failure and the individual patient.
Atrial fibrillation: rate control and clot prevention
In atrial fibrillation, rate-control medicines—including and selected —slow conduction or heart rate. reduce the formation or growth of blood clots and may be prescribed to reduce stroke risk based on clinical assessment.
These medicines are not interchangeable: a beta-blocker can help control heart rate, while an anticoagulant addresses clot-related stroke risk when indicated. Do not stop or change either medicine without professional advice.
Monitoring and safe medication changes
Common safety checks include heart rate, blood pressure, kidney function, electrolytes, electrocardiogram findings, symptoms, and interactions. Class-specific risks include ACE-inhibitor cough or angioedema, beta-blocker bradycardia, diuretic electrolyte changes, toxicity, antiarrhythmic proarrhythmia, and nitrate-related hypotension.
Do not start, stop, combine, or change cardiovascular medicines without checking with a qualified clinician or pharmacist. Seek urgent help for severe chest pain, fainting, major breathing difficulty, or signs of a serious medication reaction.